e-therapeutics reported results for the full year to Jan 31st 2018; business updates reflect good progress on the main research programs. Cash balance of £9.6mn was slightly higher than we expected, thanks to careful cost management.
e-Therapeutics (LON:ETX) focuses on the discovery of new drugs in a more efficient and effective way and aims to be a valued partner to address the productivity challenge that the pharma industry faces.
e-Therapeutics (LON:ETX) has developed a novel and unique in-silico approach to drug discovery: starting...
Dr Raymond Barlow brings with him a “broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector”, ETX said.